Daniel Christensen, APRN
Acute Care · San Antonio, TXNPI 1306288444
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,873 of the $8,431 with a category attached, or 69.7%. 15 manufacturers reported payments, led by Boston Scientific at 26.9% of the total. Reporting peaked in 2024 at $3,000 and has fallen 76.9% since, to $692 in 2025. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $68.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$2K
- Endo Pharmaceuticals Inc.$2K
- Antares Pharma, Inc.$490
- Endo USA, Inc.$421
- Johnson & Johnson$393
- plus $1K from 9 others
What the payments were for
- Consulting fees$1,39317%
- Speaking & faculty fees$1,16514%
- Food & beverage$5,87370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 26 | $2,266 |
| Medtronic | 22 | $1,850 |
| Endo Pharmaceuticals Inc. | 10 | $1,842 |
| Antares Pharma, Inc. | 20 | $490 |
| Endo USA, Inc. | 8 | $421 |
| Johnson & Johnson | 3 | $393 |
| Axonics, Inc. | 5 | $289 |
| Sumitomo Pharma America, Inc. | 6 | $230 |
| Acerus Pharmaceuticals Corporation | 10 | $134 |
| Novo Nordisk | 1 | $125 |
| AstraZeneca | 1 | $125 |
| Tolmar, Inc. | 5 | $100 |
| Coloplast | 2 | $86 |
| Halozyme Inc | 2 | $46 |
| Urovant Sciences Inc | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,431 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 66 | $51,716 |
| XyostedTestosterone Enanthate | 28 | $25,488 |
| GemtesaVibegron | 25 | $23,573 |
| Testosterone | 48 | $13,762 |
| Testosterone Cypionate | 107 | $8,872 |
| Tamsulosin Hcl | 218 | $2,861 |
| Trospium Chloride | 19 | $2,067 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 93 | $2,031 |
| Cabergoline | 19 | $1,118 |
| Finasteride | 62 | $820 |
| Pentoxifylline | 12 | $516 |
| Dutasteride | 12 | $383 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 49 | $309 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Antares Pharma, Inc.Xyosted | $490 | $25,48828 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $230 | $23,57325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in San Antonio
- Christie MorrisonSan Antonio$225K
- Jessica BjerkSan Antonio$20K
- Tara CummingSan Antonio$12K
- Erin HernandezSan Antonio$10K
- Jill FolkertSan Antonio$8K
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.